Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919203 | 1.00 | SCN8A (0.88) | SCN8ASCN10A | |
| SCHEMBL29919126 | 0.94 | SCN10A (1.00) | SCN8ASCN10A | |
| SCHEMBL15561688 | 0.94 | SCN10A (1.00) | SCN8ASCN10A | |
| Water SCHEMBL16777902 | 0.93 | SCN10A (0.98) | SCN8ASCN10A | |
| Phosphoric Acid SCHEMBL28485917 | 0.91 | SCN10A (0.94) | SCN8ASCN10A | |
| SCHEMBL15561952 | 0.88 | SCN10A (1.00) | SCN8ASCN10A | |
| SCHEMBL29919251 | 0.88 | SCN10A (1.00) | SCN8ASCN10A | |
| SCHEMBL15561664 | 0.87 | SCN8A (1.00) | SCN8ASCN10A | |
| SCHEMBL15561761 | 0.87 | SCN10A (1.00) | SCN8ASCN10A | |
| SCHEMBL29918864 | 0.87 | SCN10A (1.00) | SCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4346818-B1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4347031-B1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2022256676-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256842-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256708-A1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-3625214-B1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11358977-B2 | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210198241-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| WO-2021113627-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210155643-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-05-27 | — | — | US | disclosed |
| EP-3625214-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213426-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | SCN8A 1/4885SCN10A 22/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | SCN8A 26/4885SCN10A 37/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | SCN8A 56/4885SCN10A 94/4885 |
| US-20210198241-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | SCN8A 30/4885SCN10A 5/4885 |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, TRPA1 | SCN8A 25/4885SCN10A 9/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | SCN8A 17/4885SCN10A 10/4885 |
| US-11358977-B2 | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels | KCNH1, TRPV1, SCN1A | SCN8A 35/4885SCN10A 10/4885 |
| US-20210155643-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | KCNH1, TRPV1, SCN1A | SCN8A 35/4885SCN10A 10/4885 |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | SCN8A 15/4885SCN10A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.